Podcasts about Immunology

Support the Institute today: https://givenow.nova.edu/the-institute-for-neuro-immune-medicine-inim-2025   In this episode, Haylie Pomroy speaks with Dr. Theoharis Theoharides about the scientific foundations of brain fog. Together, they clarify its definition, physiological mechanisms, and how it presents across various illnesses and cognitive disorders. Dr. Theoharides further examines the relationship between brain fog and inflammation, explains how viral infections can contribute to the development of chronic illness, and discusses the role of microglia in neuroinflammation. He also reviews supplements that may help inhibit microglial activation, explains alpha-gal syndrome, and outlines relevant laboratory testing that can assist individuals experiencing brain fog in gaining clearer insight into their current health status. Dr. Theoharis Theoharides is a Professor, Vice Chair of Clinical Immunology, and Director at the Institute for Neuro-Immune Medicine-Clearwater, an Adjunct Professor of Immunology at Tufts School of Medicine, where he was a Professor of Pharmacology and Internal Medicine, and also the  Director of Molecular Immunopharmacology & Drug Discovery, and Clinical Pharmacologist at the Massachusetts Drug Formulary Commission (1983-2022). He received his BA, MS, MPhil, PhD, and MD degrees and the Winternitz Price in Pathology from Yale University and received a Certificate in Global Leadership from Tufts Fletcher School of Law and Diplomacy and a Fellowship at Harvard Kennedy  School of Government. He trained in internal medicine at New England Medical Center, which awarded him the Oliver Smith Award, "recognizing excellence, compassion, and service." Dr. Theoharides has 485 publications (46,491 citations; h-index 106), placing him in the world's top 2% of most cited authors, and he was rated the worldwide expert on mast cells by Expertscape. He was inducted into the Alpha Omega Alpha National Medical Honor Society, the Rare Diseases Hall of Fame, and the World Academy of Sciences. Website: https://www.drtheoharides.com LinkedIn: linkedin.com/in/theoharis-theoharides-ms-phd-md-faaaai-67123735 Instagram: https://www.instagram.com/dr.theoharides/   Haylie Pomroy, Founder and CEO of The Haylie Pomroy Group, is a leading health strategist specializing in metabolism, weight loss, and integrative wellness. With over 25 years of experience, she has worked with top medical institutions and high-profile clients, developing targeted programs and supplements rooted in the "Food is Medicine" philosophy. Inspired by her own autoimmune journey, she combines expertise in nutrition, biochemistry, and patient advocacy to help others reclaim their health. She is a New York Times bestselling author of The Fast Metabolism Diet.   Learn more about Haylie Pomroy's approach to wellness through her website: https://hayliepomroy.com   Instagram: https://www.instagram.com/hayliepomroy  Facebook: https://www.facebook.com/hayliepomroy  YouTube: https://www.youtube.com/@hayliepomroy/videos  LinkedIn: https://www.linkedin.com/in/hayliepomroy/  X: https://x.com/hayliepomroy    Enjoy our show? Please leave us a 5-star review on the following platforms so we can bring hope and help to others.   Apple Podcasts: https://podcasts.apple.com/us/podcast/hope-and-help-for-fatigue-chronic-illness/id1724900423 Spotify: https://open.spotify.com/show/154isuc02GnkPEPlWfdXMT   Sign up today for our newsletter. https://nova.us4.list-manage.com/subscribe?u=419072c88a85f355f15ab1257&id=5e03a4de7d   Enjoy our show? Please leave us a 5-star review on the following platforms so we can bring hope and help to others.   Apple Podcasts: https://podcasts.apple.com/us/podcast/hope-and-help-for-fatigue-chronic-illness/id1724900423   Spotify: https://open.spotify.com/show/154isuc02GnkPEPlWfdXMT   Sign up today for our newsletter. https://nova.us4.list-manage.com/subscribe?u=419072c88a85f355f15ab1257&id=5e03a4de7d   This podcast is brought to you by the Institute for Neuro-Immune Medicine. Learn more about us here.   Website: https://www.nova.edu/nim/ Facebook: https://www.facebook.com/InstituteForNeuroImmuneMedicine Instagram: https://www.instagram.com/NSU_INIM/ Twitter: https://www.twitter.com/NSU_INIM

Matters Microbial #119: Investigating Microbial "Dark Matter" December 22, 2025 Today Dr. Julia Willett, Assistant Professor in the Department of Microbiology and Immunology at the University of Minnesota, joins the #QualityQuorum to discuss how to investigate unknown genes found in nearly every bacterial genome. Call it Microbial Dark Matter! Host: Mark O. Martin Guest: Julia Willett Subscribe: Apple Podcasts, Spotify Become a patron of Matters Microbial! Links for this episode Microbial "Dark Matter"—unknown genes in microbial genomes. The process of annotation. An article about the "Y-ome" or understanding "uncharacterized" genes. The smallest independently growing (and engineered) bacterium, JCVI-syn3.0. It still has many "uncharacterized" but necessary genes. An essay on Enterococcus faecalis.  Diseases caused by Enterococcus. The concept of the pathobiont. Dr. Arturo Casadevall's thoughts on the term "pathogen." The use of transposon mutagenesis to create "knock outs" of bacterial genes. Array transposon mutagenesis. Here is an article coauthored by Dr. Willett on that topic. The Alpha Fold program for predicting gene function. A webinar describing "Microbial Dark Matter" by Dr. Willett. Dr. Willett's faculty website. Dr. Willett's laboratory website. Intro music is by Reber Clark Send your questions and comments to mattersmicrobial@gmail.com

Professor Luke O'Neill, School of Biochemistry and Immunology at Trinity College Dublin

Co-hosts Ryan Piansky, a graduate student and patient advocate living with eosinophilic esophagitis (EoE) and eosinophilic asthma, and Holly Knotowicz, a speech-language pathologist living with EoE who serves on APFED's Health Sciences Advisory Council, interview Fei Li Kuang, MD, PhD, an allergist and immunologist, at Northwestern Medicine, about receiving two APFED HOPE on the Horizon Grants. Disclaimer: The information provided in this podcast is designed to support, not replace, the relationship between listeners and their healthcare providers. Opinions, information, and recommendations shared in this podcast are not a substitute for medical advice. Decisions related to medical care should be made with your healthcare provider. Opinions and views of guests and co-hosts are their own.   Key Takeaways: [:50] Co-host Ryan Piansky introduces this episode, brought to you thanks to the support of Education Partners GSK, Sanofi, Regeneron, and Takeda. Ryan introduces co-host Holly Knotowicz.   [1:14] Holly introduces today's topic, two APFED HOPE on the Horizon Pilot Grant Projects and today's guest, Fei Li Kuang, MD, PhD, an Assistant Professor in the Division of Allergy and Immunology at Northwestern University Feinberg School of Medicine in Chicago, Illinois.   [1:42] Dr. Kuang is a physician-scientist who takes care of patients with eosinophilic disorders and also performs laboratory research on these disorders in her lab, often using patient samples. Holly thanks Dr. Kuang for joining us.   [2:05] As a child, Dr. Kuang always wanted to be a scientist. She is so grateful to live out her childhood dream, and it's because of the amazing people who have supported her, most importantly, her parents.   [2:29] In graduate school, Dr. Kuang studied B cells. When she went on to do an allergy fellowship, she thought she would study B cells and care for patients with B cell problems. Instead, she fell in love with allergy and eosinophilic disorders.   [2:50] Dr. Kuang is here, in part, because of the different mentors she has had, and in large part, because of the patients she has met along the way.   [3:20] Dr. Kuang had the opportunity to work with Amy Klion at the NIH in a clinical trial to treat patients with a drug that gets rid of eosinophils. She says it was a dream come true after her training.   [4:02] She says she learned so much about eosinophils, their unusual biology, and the mystery behind what they are here for. She got hooked.   [4:15] Dr. Kuang thinks the patients you meet in a clinical trial in a special place like NIH occupy a space in your heart that makes you want to keep working on the subject area.   [4:34] Patients in a clinical trial have given up a bunch of their time to travel to Bethesda, Maryland. For the trial Dr. Kuang participated in as a Fellow, it was a good year of their time to come out and do it.   [4:47] Dr. Kuang felt there were so many interesting questions, from an intellectual point of view, but there was also a real need from patients with chronic conditions. It was a beautiful opportunity to marry scientists with physicians in training.   [5:36] Dr. Kuang shares some knowledge about eosinophils. They are white blood cells that are in all of us. They have little pink packages or granules that "jumped out" in the light microscope almost 200 years ago, when we first identified them.   [6:00] Dr. Kuang says that animals, dating back to reptiles, and different species of dolphins, all have eosinophils. A veterinary scientist, Dr. Nicole Stacy of the University of Florida, has taken photos of eosinophils from all these different species.   [6:21] They've been around for a long time. What are they good for? What we know is that they are associated with disease conditions, such as asthma and others, including leukemia. Those were the classic first studies of eosinophils.   [6:42] Now, we have a different mindset about eosinophils from work by the late James Lee at Mayo Clinic, Arizona.   [6:58] Dr. Kuang credits Dr. Lee with suggesting that eosinophils not just cause us problems but also help treat parasitic infections, maintain tissue homeostasis, help wound healing, and tissue repair. That's a new area we are beginning to appreciate.   [7:41] Dr. Kuang says we need to be open-minded that in some circumstances, eosinophils may be helpful or innocent. Now we have tools to start to understand some of that. We need to collect information from patients being treated with medicines.   [8:10] Ryan tells of being diagnosed as a kid. Doctors explained to him that eosinophils fight parasites, but in some people, they get confused and attack the esophagus. That's EoE. That was easy to understand, but he knew that the researchers knew more.   [8:53] Ryan is grateful to the patient population around eosinophilic esophagitis, and is proud of APFED's support of patients and caregivers with HOPE Grants. APFED has the HOPE on the Horizon Research Program, entirely funded by community donations.   [9:13] To date, APFED has directed more than $2 million toward eosinophilic disease research initiatives through various grant programs. As a patient advocacy organization, APFED works with fantastic researchers who submit innovative research ideas.   [9:32] These research ideas go through an extensive and competitive peer-review process, supported by researchers and clinicians in the APFED community.   [9:42] Today, we're going to discuss two different projects supported by HOPE Pilot Grants with Dr. Kuang.   [10:00] Dr. Kuang thinks there are two ways these grant programs are important to patients. One is advancing research by nurturing seedling investigators. Dr. Kuang got her first grant when she was a Fellow. It was an incredible opportunity.   [10:25] These grant programs also nurture seedling ideas that don't have enough evidence yet to garner the larger NIH grants, and so forth. There are other sources for grants: pharmaceutical companies. The grant programs are for seeds.   [10:49] Patients need to know that there are new things that are given some chance of being tested out. Research takes some time, and the FDA process of getting a drug approved is long.   [11:04] For the newly diagnosed patient, it can feel overwhelming. It feels like there's a loss of control. Sometimes, participating in something like APFED, being part of a community, gives back a sense of control that is lost when you're handed a diagnosis.   [11:45] For patients who have had it for a long time, when they participate in research and become engaged in organizations like APFED, they know they may not directly benefit today, they may benefit later, but they hope future patients will benefit.   [12:21] That gives them a sense of control and hope that things will be better for the next generation. We all want that, especially in medicine, in something that we don't have a very deep understanding of.   [12:58] Dr. Kuang received two HOPE Pilot Grants, one in 2018 and one in 2022. The first grant was awarded when she was a Fellow at the NIH.   [13:05] That first grant explored some effects of eosinophilic depletion of pathogenic lymphocytes in hypereosinophilic syndrome and overlaps with EGIDs. Ryan asks for a broad overview of that research.   [13:25] When Dr. Kuang was a Fellow at the NIH, they were doing a Phase 2 clinical trial, looking at "blowing up" eosinophils in patients who have a lot of them, hypereosinophilic syndrome patients.   [13:39] They included patients who had eosinophilic GI disease, often beyond the esophagus. They may have esophageal involvement, but sometimes their stomach is impacted, sometimes their large bowel is impacted, with related symptoms.   [13:57] What Dr. Kuang and the team noticed in the trial was that just within that little group of patients, there were people who did well, and people who did much better than before, but would have recurrent symptoms, and with no eosinophils in their GI tissues.    [14:16] The researchers wanted to know what was causing these problems for the patient. If you take eosinophils away, what other factors will impact the immune system of the patient, semi-long-term?   [14:32] Their focus was on these groups of patients who had different responses. They looked at the white blood cells that had been previously described as being the responsible, "bad" T cells that lead to eosinophils in the gut.   [14:49] They found that the patients who had recurrent flares of the disease had more of the bad T cells, and the patients who responded well and never complained again about symptoms did not.   [15:03] That allowed researchers to identify that there were subsets of patients with the disease that they were calling the same thing.   [15:18] Dr. Kuang says that work also led them to find that those cells were being reported in patients who had food allergies for which they needed an epinephrine auto-injector.   [15:27] The researchers were curious whether that was just a food allergy issue, or only applied if you had food allergies and eosinophilic GI disease. That HOPE project allowed them to do a pilot study to look at food allergy patients, too. They did, and published it.   [15:45] They published that in patients who have a food allergy and have these T cells, the insides of those cells make different messages for the immune system than the ones that the researchers had previously described.   [16:01] In looking for why there were differences in those responses, they accidentally found that there were differences inside these cells in a completely different disease, which also had these T cells.   [16:21] Dr. Kuang says that the finding was kind of a surprise. If they had found anything in the eosinophilic GI disease patients, that would have been good. They also looked at the epithelial cells and the structure of the GI lining.   [16:42] Even though there were no eosinophils in the GI lining in the patients who had been treated with a biologic that depleted eosinophils, their GI lining still looked like the GI lining of patients who had eosinophilic GI disease.   [16:55] Dr. Kuang asked what was creating those spots. Our gut lining sheds, so there should have been an opportunity for the GI lining to turn over and look new. Something was there, making signals to create these spots. They did a different publication on that.   [17:21] The data from the HOPE Pilot study allowed Dr. Kuang to apply for larger grants. It allowed her to propose to the company that made this drug, when they did the Phase 3 trial, to insert into that special study the study on eosinophilic GI disease.   [17:48] Do patients with eosinophilic GI disease do better or worse on this drug, and how do the T cells look in that trial? That HOPE Grant gave Dr. Kuang the data to ask the drug company to give her money to study it in an international cohort of patients.   [18:17] There were only 20 patients in that first NIH trial, who gave a year of their life, coming to NIH all the time. They continued to be in the study until the drug was approved for asthma.   [18:28] Dr. Kuang says the main reason the company did the Phase 3 trial, which is expensive, and the market share is not huge because it's a rare disease, is that two of the patients went to bat for this disease population.   [18:47] The two patients went and showed the business people what they looked like before, what the drug had done for them, and how their lives had changed. It wasn't the doctors or the great paper from the trial, but the patients who convinced the company.   [19:01] Dr. Kuang says she was so floored by that and moved by what they did for the community. She is grateful.   [19:24] Since the Phase 3 trial, Dr. Kuang and the other researchers realized they had not fully studied the eosinophils. They had studied them in part. They found differences in response. This inspired the second APFED HOPE Pilot Grant.   [21:19] In 2022, Dr. Kuang received a two-year APFED HOPE Pilot Grant to examine how blood eosinophils in Eosinophilic Gastrointestinal Diseases differ from those of other eosinophilic diseases and how T cells in EGIDs differ from those in food allergies.   [21:49] Dr. Kuang says normally, the biggest place of residence for eosinophils is the GI tract. That's where they are normally seen in people who do not have eosinophilic disorders.   [21:59] People who have eosinophilic disorders that attack other parts of the body, asthma, and rarely, the heart. Dr. Kuang was curious to know why one person and not the other?   [22:15] Patients who have eosinophilic GI disease often ask, How do you know this high level in the blood is not going to attack my heart or my lungs in the future? Dr. Kuang does not know.   [22:29] Dr. Kuang says, looking at the cohort at the NIH, that for many patients who have both GI organ involvement and some other space, when they first went to see a provider, their first complaint was a GI condition.   [22:54] If the doctor had only diagnosed a GI condition, nothing else, that would have been wrong. Those patients may not have been monitored as well. A third of the patients originally presented like that.   [23:11] What that meant was that we should be paying attention to patients who have GI disease who have lots of eosinophils in their blood. Moving forward, if there are new complaints, we need to investigate. We can't forget they have that.   [23:27] Dr. Kuang asks, Wouldn't it be great if we had a better tool than needing to wait? Wouldn't it be great if we had a biomarker that said the eosinophils have switched their target location and are going somewhere else?   [23:41] One way to do that is to take different groups of eosinophils and look for differences between those that never target the GI tract and those that do. In patients who have EoE, the eosinophils only target or cause problems in the esophagus.   [23:58] Are their eosinophils any different than those of a healthy person, with none of these conditions? That was the goal of that study.   [24:10] T cells are another type of white blood cell. They contain a memory of foreign things they have encountered, which allows them to glom onto flu, COVID, peanuts, pollen, that kind of thing. They remember.   [24:32] Dr. Kuang says they learned that T cells, at least in the mouse model, are required in the development of eosinophilic esophagitis. The mice in the old study, where mice were forced to develop EoE, did not get EoE if you removed their T cells.   [24:50] In the first APFED HOPE grant study, Dr. Kuang found T cells in the blood and tissue of both EGIDs and food allergy patients, but the insides of the T cells were different. The food allergy patients were children recruited by a pediatric allergist.   [25:19] In the second APFED HOPE grant study, at Northwestern, Dr. Kuang recruited her adult food allergy patients. That was a way to validate what they found in the first study and move further to better characterize those T cells in the two different diseases.   [25:47] Dr. Kuang says we're at a point where we've recruited a lot of people. She says it's amazing what people are willing to do. It's very humbling.   [26:06] Dr. Kuang's team in the lab is really great, too. To accommodate patients, they would see them after work, if that's what they had to do to isolate eosinophils. So they did that, and now they are in the process of analyzing that data. It's really exciting.   [26:28] What's exciting is that they are seeing results that show that eosinophilic GI disease patients have circulating eosinophils that are different from the eosinophils of people who don't have GI involvement, and from people who have EoE.   [26:46] The EoE patients have eosinophils different from those of healthy donors. Dr. Kuang says there's a lot of promise for perhaps unique signatures that could help define these conditions; maybe someday without biopsying, but that's a long time away.   [27:16] Dr. Kuang says they will focus on some candidate targets and try to recreate some of that in a dish with eosinophils from healthy people.   [27:26] What are the signals that lead eosinophils to do this, and can we translate that back to available drugs that target certain cytokines or other pathways, and maybe give some insight to develop drugs that target other pathways for these diseases?   [28:17] Ryan thinks it's exciting that this research is narrowing in on not only the different symptoms, but also how the eosinophils are acting differently in these populations.    [28:44] Dr. Kuang is super excited about this research. You could imagine that all eosinophils are the same, but you don't know until you look. When they looked, using the newest technology, they found there were differences.   [29:33] Dr. Kuang says it is thought that T cells respond to triggers. We don't think eosinophils have a memory for antigens. T cells do. That's one of their definitions. When T cells react to a trigger, they give out messages through cytokines or by delivery.   [30:20] Those are the messages that recruit eosinophils and other cells to come and stir up some trouble.   [30:28] In the mouse model, where you don't have the T cells, and you don't get eosinophilic esophagitis in the particular way they made it happen in a mouse, that middle messenger is gone, so the eosinophils don't know where to go.   [30:44] With drugs that take out eosinophils, you think that you've gotten rid of the cell that creates all the problems. It shouldn't matter what the message says because there's no cell there to cause the damage.   [30:58] What Dr. Kuang learned is that, at least in certain eosinophilic GI diseases, that's not true. You erase the eosinophils from the picture, but that message is still coming.   [31:10] Who's carrying out the orders? Or is that message maintaining the wall of epithelial cells in a certain way that we didn't appreciate because the eosinophils were also there?   [31:24] It's important to study both, because one is the messenger and the other is one of the actors. Whether all of the actions taken by eosinophils are bad, or maybe some of them were meant to be good, we have yet to learn.   [31:40] At the moment, we're using it as a marker for disease activity, and that may change in the future, as we learn more about the roles of these cells in the process.   [31:50] We have drugs now that target eosinophils and drugs that target T cells. Dr. Kuang thinks it's important to study both and to study the impact of these drugs on these cells.   [32:02] You could theoretically use these drugs to understand whether, if someone responds to it, what happens to these cells, and if someone doesn't respond to it, what happens to these cells, and how this disease manifests in this flavor of patients.   [32:54] Dr. Kuang says, Often in science, we take a model. We think this works this way. Then, if this works this way, we expect that if we remove this, these things should happen. We did that with the first clinical trial, with NIH patients.   [33:10] It didn't quite happen the way we thought, so we had to go looking for explanations. These were unusual setbacks. Sometimes you have unusual findings, like the food allergy part.   [33:24] When Dr. Kuang went to Northwestern, she saw different cohorts of patients than she saw at NIH. She saw people who were seen every day, which is a different spectrum than those who are selected to be enrolled in a study protocol at the NIH.   [33:42] That broadened her viewpoint. It's maybe not all food-triggered. They were seeing adults who'd never had food allergies or asthma their whole life, and they had eosinophilic esophagitis suddenly as a 50-year-old. There's a significant group of them.   [34:10] What Dr. Kuang learned and tries to be open-minded about is that where you train, what sorts of patients you see, really shape your viewpoint and thinking about the disease process and the management process.   [34:24] Dr. Kuang says she was so lucky to have experienced that at a quaternary care referral center like the NIH and at an academic center like Northwestern, where there are fantastic gastroenterologists who see so many of these patients.   [34:56] Dr. Kuang and an Allergy Fellow knew they were going to get a wonderful data set from the NIH patients they had recruited, so they thought they had better look deeply at what had been learned before with older technology, with mice and people.   [35:13] They decided to gather previous research, and that ultimately got published as an article. From that research, they learned that people did things in many different ways because there was no standard. They didn't know what the standard should be.   [35:28] Different things you do to try to get eosinophils out of tissue impact how they look, in terms of transcript, gene expression, and what messages they make to define themselves as an eosinophil.   [35:43] They also learned that because eosinophils are hard to work with, they die easily, and you can't freeze them and work on them the next day; you can introduce issues in there that have to be accounted for.   [35:59] They learned that as an eosinophil research community, they ought to come up with some standards so that they can compare future studies with each other. Dr. Kuang says it was impossible to compare the old studies that used different premises.   [36:50] Dr. Kuang says we need to be proactive in creating the datasets in a standard way so that we can compare and have a more fruitful and diverse community of data. It's hard to use the old data.   [37:57] Dr. Kuang says they get fresh blood from patients, and because eosinophils are finicky, they need to be analyzed within four hours, or preserved in a way to save whatever fragile molecules are to be studied.   [38:19] If you let it sit, it starts dying, so you won't have as many of them, and they start changing because they're not in the body. Dr. Kuang experimented with putting a tube of blood on the bench and checking it with the same test every two hours. It changes.   [38:38] Four hours is a standard to prevent the eosinophils from dying. Patients need treatment. If a patient is hospitalized and needs treatment, Dr. Kuang's team needs to be there to get a sample before treatment is started.   [39:03] The treatment impacts it, changing the situation. Much of the treatment, initially, is steroids. When you give lots of steroids, the eosinophils go away. It's no good to draw their blood then.   [39:27] Dr. Kuang also gets a urine sample. The granules of the eosinophils can get into the urine. As they study people with active disease, they want to capture granule proteins in the urine as a less invasive way to monitor activity in different disease states.   [40:04] The patient just needs to give Dr. Kuang either arm and a urine sample.   [41:04] Dr. Kuang explains, you can count your eosinophils after four hours, but to study them, they have different flags of different colors and shapes. Those colors and shapes may mean that it's an activated eosinophil, or they may have other meanings.   [41:41] Dr. Kuang focused on markers that look at whether it's going to spill its granules and some traditional markers of activation.     [41:50] Everyone chooses a different marker of activation. So they decided to look at as many as they could. One marker is not sufficient. They seem to be different in different conditions. The markers are on the surface; you need to analyze them right away.   [42:20] Then, Dr. Kuang breaks open the eosinophils and grabs the messenger RNA. They preserve it to do sequencing to read out the orders to see what this eosinophil is telling itself to make. RNA chops up messages.   [43:00] When you open an eosinophil, a protein you find is RNA, which chops up messages, destroying parts of the cell. You want to save the message. There's a brief time to analyze the eosinophil. Dr. Kuang works to preserve and read the message.   [44:04] Dr. Kuang hopes someday to run a tube of blood, look at the flags on the eosinophils, and say, "I think your eosinophilic GI disease is active," or "You have a kind of eosinophilic GI disease we need to monitor more frequently for organ damage."   [44:38] If another patient doesn't have those flags, Dr. Kuang could say, "I think the chances that you're going to have involvement elsewhere are low." That can give reassurance to folks who are worried.   [45:15] Dr. Kuang hopes that someday we can understand better why some people have food allergies vs. eosinophilic GI disease. They both have T cells, but the T cells have different packages inside with messages to deliver.   [45:34] Every day, Dr. Kuang has to tell patients she doesn't have that answer. Someday, she hopes she can tell a patient she does have that answer.   [46:35] Dr. Kuang tells about an NIH grant she's excited about and the patients she recruits after therapy, or elimination diets, to examine eosinophils and T cells, to see the impacts their treatments or diets have had on eosinophilic GI disease.   [47:18] Dr. Kuang believes there will be predictors of who will respond to an elimination diet and who will respond to steroid therapy. She hopes one day to have that, rather than going through rounds of six to eight weeks followed by a scope.   [47:34] If you have an elimination diet for six to eight weeks, every time you add back a food, you have to do a scope. Dr. Kuang says it would be great if you could be more precise ahead of time for therapy.   [47:48] Dr. Kuang says these wonderful drugs selectively take out parts of the pathway in the immune system. They provide real-life opportunities to ask, why is this important in human biology and the human immune system?   [48:15] Dr. Kuang finds the knowledge itself fascinating and useful. She hopes it informs how we choose future drugs or therapeutic avenues to get the best we can out of what we've learned, so we have more targeted ways of treating specific diseases.   [48:48] Ryan is grateful for all the research happening for the eosinophilic disease community and all the patients participating in the research. He asks Dr. Kuang how a patient can participate in research.   [49:12] There are lots of ways to be involved in research. Dr. Kuang says her patients come away from participating in research feeling good about having done it.   [49:22] Answer a survey, if that's what you have bandwidth for. Where therapies are changing, being a part of a community is good for the community, for the future, but it's good for you, too. It's healing in ways that are not steroids or biologics.   [49:58] Being part of a community is healing in ways we all need when we feel alone and bewildered. You're not alone.   [50:12] There are many ways to participate: APFED, CEGIR, individual institutions, and clinical trials. They all have different amounts of involvement. It's worthwhile to participate, not only for future patients but for yourself. They're fantastic!   [50:56] Dr. Kuang talks about the privilege as a physician of working with APFED and other organizations to do this work.   [51:09] Holly thanks Dr. Kuang for sharing all of this research and exciting information.   [51:25] Dr. Kuang is excited about what her group is doing and is hopeful. Besides showing up for this disease, we have to show up for research, in general, in this country. It's a dark time for NIH research funding.   [51:55] Dr. Kuang asks the young listeners who are thinking of choosing a field to see the potential and get into it, study this, and believe that there's going to be a future with a more nurturing research environment.   [52:36] Dr. Kuang would hate to lose generations of scientists. She says that once she was a little girl who was trying to be a scientist. Her parents had no connections with scientists or doctors, but she was able to get into research, and she thinks you can, too.   [53:48] As a graduate student, Ryan has always been interested in trying to improve things, and he sees hope on the horizon. He's very grateful to the APFED community for supporting these research HOPE Pilot Grants.   [54:17] Ryan is very grateful to Dr. Kuang for joining us today.   [54:22] For our listeners who want to learn more about eosinophilic disorders, we encourage you to visit apfed.org and check out the links in the show notes.   [54:28] If you're looking to find a specialist who treats eosinophilic disorders, we encourage you to use APFED's Specialist Finder at apfed.org/specialist.   [54:37] If you'd like to connect with others impacted by eosinophilic diseases, please join APFED's online community on the Inspire Network at apfed.org/connections.   [54:57] Dr. Kuang thanks Ryan and Holly and says she enjoyed the conversation. Holly also thanks APFED's Education Partners GSK, Sanofi, Regeneron, and Takeda for supporting this episode.   Mentioned in This Episode: Fei Li Kuang, MD, PhD, Allergist and Immunologist, Northwestern Medicine   Grants and publications discussed: Apfed.org/blog/apfed-announces-2018-hope-apfed-hope-pilot-grant-recipient/ Apfed.org/blog/fei-li-kuang-hope-pilot-grant-award/  Pubmed.ncbi.nlm.nih.gov/39213186/ Pubmed.ncbi.nlm.nih.gov/37487654/   APFED on YouTube, Twitter, Facebook, Pinterest, Instagram Real Talk: Eosinophilic Diseases Podcast apfed.org/specialist apfed.org/connections apfed.org/research/clinical-trials   Education Partners: This episode of APFED's podcast is brought to you thanks to the support of GSK, Sanofi, Regeneron, and Takeda.   Tweetables:   "I think the patients that you meet in a clinical trial, especially in a special place like NIH, occupy a space in your heart — I don't mean to be all too emotional about this — that makes you want to keep working on the subject area." — Fei Li Kuang, MD, PhD   "When I was a Fellow at the NIH, we were doing a Phase 2 clinical trial, looking at, for want of a better word, "blowing up" eosinophils in patients who have a lot of them, hypereosinophilic syndrome patients." — Fei Li Kuang, MD, PhD   "We're at a point where we've recruited a lot of people. I've had patients drive from the northern part of Illinois … come down and give me blood. It's amazing what people want to do and are willing to do. It's very humbling, actually." — Fei Li Kuang, MD, PhD   "You erase the eosinophils from the picture, but that message is still coming. Who's carrying out the orders? Or is that message maintaining the wall of epithelial cells in a certain way that we didn't appreciate because the eosinophils were also there?" — Fei Li Kuang, MD, PhD   "We need to be proactive in creating the datasets in a standard way so that we can compare and have a more fruitful and diverse community of data." — Fei Li Kuang, MD, PhD   "I think it's worthwhile to participate [in a clinical trial], not only for the future people but for yourself." — Fei Li Kuang, MD, PhD   Guest Bio: Fei Li Kuang, MD, PhD, is currently an Assistant Professor in the Division of Allergy and Immunology at Northwestern University Feinberg School of Medicine in Chicago, IL. She is a graduate of the Albert Einstein College of Medicine Medical Scientist Training Program with both a PhD in Cell Biology/Immunology and an MD.  She completed her Internal Medicine Residency at Columbia University, New York Presbyterian Hospital in New York City, she did her Fellowship in Allergy and Immunology at the National Institute of Allergy and Infectious Disease (NIAID) in Bethesda, Maryland. She is a physician-scientist who takes care of patients with eosinophilic disorders and also performs laboratory research on these disorders in her lab, often using patient samples.

Episode: 1490 Germs, John Snow, and the Broad Street Well.  Today, we talk about germs.

Kingston Mills, Professor of Experimental Immunology at the School of Biochemistry and Immunology at Trinity College Dublin, Brendan Horan, Principal of Bunscoil na Cathrach in Cahir Co Tipperary and Vincent McAviney, London based journalist discuss the flu season.

In this episode presented by AnaptysBio, Jennifer Smith-Parker speaks to Dr. Joe Murray, professor of medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, and Department of Immunology, The Mayo Clinic; Marilyn Gellar, CEO, The Celiac Disease Foundation; and Dr. Paul Lizzul, chief medical officer, AnaptysBio, about the unmet need for effective treatments for celiac disease, the limitations of the gluten-free diet and the development of ANB033, a first-in-class CD122 antagonist designed to modulate IL-2/IL-15 signaling.HostJennifer Smith-Parker, Director of Insights, BioSpaceGuestsDr. Joe Murray, Professor of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine and Department of Immunology, The Mayo ClinicMarilyn Geller, CEO, Celiac Disease FoundationDr. Paul Lizzul, Chief Medical Officer, AnaptysBio Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

“We should stop being scared of food, and we really should just let babies eat.”                                                                                                          — Dr. Carina VenterDr. Mariam Hanna sits down with Dr. Carina Venter, a leading dietitian and researcher in food allergy prevention and management. They get into the everyday realities of feeding infants and children in allergy practice, from early introduction to texture challenges, growth concerns, and the rise of allergen-free processed foods.On this episodeHow nutrition supports the microbiome and immune system, and helps clinicians navigate the anxiety common in food-allergy clinics.Practical early-feeding strategies: pairing low-allergen foods with allergens, starting early, and keeping allergens in the diet once introduced.How to approach families whose infants reject certain textures or flavours, and realistic ways to incorporate allergens like egg and peanut.Why baby-led weaning may not work well for allergenic foods, especially in babies with eczema.Nutritional red flags: milk allergy, multiple food allergies, and texture delays that warrant dietitian referral.Concerns about ultra-processed allergen-free products and how emulsifiers may affect gut health.This episode brings nutrition back to the centre of allergy practice. Dr Venter's guidance keeps things practical — diverse diets, consistent allergen exposure, and attention to growth and texture — so families can feel confident and kids can learn to enjoy food safely.Visit the Canadian Society of Allergy and Clinical ImmunologyFind an allergist using our helpful toolFind Dr. Hanna on X, previously Twitter, @PedsAllergyDoc or CSACI @CSACI_caThe Allergist is produced for CSACI by PodCraft Productions

About this episode: After recovering from an illness like the flu or mononucleosis, most of us will return to our normal lives without complications. But for some, viruses can linger in the body—sometimes for years—and reemerge, wreaking new havoc on the immune system and even triggering chronic diseases. In this episode: Virologist Maggie Bartlett explains how viruses—many of which are vaccine-preventable—can cause post-acute infection syndrome and what's needed to improve the diagnosis and treatment of these conditions. Watch the video version of this episode. Guests: Maggie L. Bartlett, PhD, is an assistant research professor in Molecular Microbiology and Immunology at the Johns Hopkins Bloomberg School of Public Health and the co-host of "Why Should I Trust You?". Host: Lindsay Smith Rogers, MA, is the producer of the Public Health On Call podcast, an editor for Expert Insights, and the director of content strategy for the Johns Hopkins Bloomberg School of Public Health. Show links and related content: Vaccines Do More Than Prevent Disease—Johns Hopkins Bloomberg School of Public Health The Virus That Never Leaves—Dr. Maggie's Substack What We Know—And Still Don't Know—About Long COVID—Public Health On Call (October 2025) Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

Professor Conor Deasy, Consultant in Emergency Medicine at Cork University Hospital; Christine Loscher, Professor of Immunology at Dublin City University; and Tadgh Daly, CEO of Nursing Homes Ireland

Send us a textLatinos have changed global science in extraordinary ways—and most people never learned their names. In this episode of The Global Latin Factor Podcast, Crispin Valentin highlights three groundbreaking Latino scientists whose discoveries reshaped public health, immunology, and modern medicine.

Jack Cowan from the University of Ottawa interviews Dr. Morgan Fullerton, a Professor in the Department of Biochemistry, Microbiology and Immunology, on behalf of his team in the TMM4950 Science Communication course. Dr. Fullerton discusses dysregulated cholesterol metabolism, a hallmark of atherosclerotic cardiovascular diseases. He delves into his lab's recent study examining whether AMPK, the cell's energy sensor, truly protects against atherosclerosis by limiting cholesterol production, where his team made an unexpected discovery that challenged long-standing assumptions in cardiovascular research.Learn more: https://www.fullertonlab.com/0:00 | Introduction1:34 | Introduction of guest (Dr. Morgan Fullerton)2:35 | What is atherosclerosis?4:05 | The cell's energy sensor (AMPK)5:25 | Targeting AMPK|HMGCR to protect against atherosclerosis7:42 | What was expected when AMPK's control was removed?8:32 | Importance of validating a disease model10:25 | Does removing AMPK change atherosclerosis?12:53 | Future therapies13:52 | Commentary (provided by Dr. Emily Day) and conclusion Music is non-copyrighted and free for use.Jack Cowan (Host), Toshka Besharah (Writer), Melissa Barnett (Producer)

Ananya Jain from the University of Ottawa interviews Dr Adam Rudner about advances in temperate bacteriophage research. Dr. Rudner is a researcher and associate professor in the Department of Biochemistry, Microbiology and Immunology at the University of Ottawa. He also co-leads the Howard Hughes Medical Institute (HHMI) Science Education Alliance-Phage Hunters Advancing Genomics and Evolutionary Science (SEA-PHAGES) associated bacteriophage discovery lab for students in the Translational and Molecular Medicine Program at the University of Ottawa. In this episode, Dr. Rudner discusses bacteriophage basics, the current state of bacteriophage therapy, and how temperate bacteriophages could be harnessed in the future of bacteriophage therapy. Dr Rudner also highlights novel discoveries in the field of temperate bacteriophage biology by discussing his own lab's discovery of a new lysogeny mechanism and discussing the work of Dr. Alex Hynes, a researcher and associate professor at McMaster University, who discovered temperate phage antibiotic synergy (tPAS).Learn more: https://www.uottawa.ca/faculty-medicine/directory/dr-adam-rudner0:00 | Introduction to the Podcast0:29 | Introduction to Dr. Adam Rudner1:16 | What inspired Dr. Rudner to pursue bacteriophage research2:23 | The differences between lytic and lysogenic bacteriophages3:26 | The importance of researching bacteriophages and their therapeutic potential4:57 | Discussing the work of Dr. Alex Hynes and his discovery of temperate phage antibiotic synergy (tPAS)7:12 | Advancements required to implement temperate phages and tPAS in therapeutics8:25 | The discovery of a novel lysogeny mechanism by Dr. Rudner's lab13:50 | Key Takeaways14:27 | Concluding RemarksSoundtrack by The Underground Drive. All rights reserved. Listen more:https://music.apple.com/ca/artist/the-underground-drive/1571062779https://open.spotify.com/artist/4sCJG8TMQyTZ9FDd1JjJmRAnanya Jain (Host), Rebecca Santhosh Babu (Writer), Mirabel Joseph (Social Media Coordinator), Amber Morton (Producer)

- Geopolitical Developments and Book Updates (0:10) - Introduction to Terawatt Tantrums (2:26) - Challenges in Power Infrastructure (5:46) - Nuclear Power and Dependence on Russia (10:33) - Challenges in Building Nuclear Power Plants (15:02) - Alternative Energy Sources and Challenges (20:53) - China's Lead in AI and Power Infrastructure (23:45) - The Future of AI and Power in the U.S. (52:42) - Brighteon Book Engine Updates (52:59) - Censorship and the Role of AI (1:20:32) - Censorship and the Truth About Money (1:22:53) - Censorship in the Ukraine-Russia Conflict (1:30:35) - Censorship in Virology and Immunology (1:33:33) - Censorship in Evolution and Climate Change (1:41:12) - Censorship and Depopulation Agendas (1:46:55) - Introduction to "Terawatt Tantrums" (1:48:52) - China's Energy Advantage (1:52:41) - The Importance of Energy Independence (1:53:00) - Call to Action for Energy Independence (1:54:18) - Promotion of Health Ranger Products (1:58:01) For more updates, visit: http://www.brighteon.com/channel/hrreport  NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we're helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency. ▶️ Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/ ▶️ Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html ▶️ Brighteon: https://www.brighteon.com/channels/hrreport ▶️ Join Our Social Network: https://brighteon.social/@HealthRanger ▶️ Check In Stock Products at: https://PrepWithMike.com

Legendary Stanford immunologist Dr. Ed Engleman helped create the foundations of modern cancer treatment. From early breakthroughs in immune-cell training to a brand-new discovery, Engleman explains how the immune system can now be switched on and off like circuitry, with implications for cancer, autoimmune disease, infections and more. He also breaks down his role at Vivo Capital, the global life-sciences venture firm where he evaluates and guides new biotech startups. Engleman describes how Vivo's more conservative, data-driven investment style matches his own approach: digging deep into the science, waiting for real clinical signals, and backing teams that can translate discoveries into actual drugs. A rare conversation with a scientist-founder-investor whose discoveries and companies have reshaped medicine — and who's still chasing the next breakthrough. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Pancreatic cancer is one of the most fatal malignancies, with most patients diagnosed only after the disease has already spread. For those with metastatic cancer, the five-year survival rate sits at just 2–3 percent, and median survival is typically measured in months. A breakthrough study from researchers at UCLA could be a pivotal shift in treatment.Professor Luke O'Neill, Professor of Biochemistry at the School of Immunology, Trinity College brings us the details.

Find More Great Info From Dr. Melanie Matheu Here: SUBSTACK: https://lilscience.substack.com TIKTOK:https://www.tiktok.com/@laughterinlight YOUTUBE: https://www.youtube.com/@LaughterInLight Hawk talks with immunologist Dr. Melanie Matthew about the upcoming flu season and the devastating impact of RFK Jr as HHS Secretary. Australia experienced record-setting influenza deaths this year, with flu killing more people than COVID. The H3N2 variant mutated to evade vaccine protection, leading to unprecedented hospitalizations. Japan declared a flu epidemic five weeks early, and similar patterns are emerging in the United States.Dr. Matthew explains why flu vaccination remains critical despite mutations, reducing hospitalizations by 30-40% in adults and 70-75% in children. The conversation shifts to RFK Jr's anti-vaccine policies at HHS, where he claims no vaccine is safe and effective despite having zero background in immunology or pediatrics. His appointment, along with Marty Makary at FDA and Jay Bhattacharya at NIH, represents a complete rejection of scientific reality in favor of political ideology.The discussion covers RFK Jr's role in 88 child deaths in Samoa from measles, his vitamin A recommendations causing liver damage in Texas children, and how VAERS data is being misrepresented. Dr. Matthew details the exodus of top scientists from NIH, cancelled research grants, and terminated clinical trials that will kill patients. Forever chemicals (PFAS) are being approved for pesticides while vaccine research funding gets slashed.America faces losing measles elimination status, rising preventable disease deaths, and compromised pandemic preparedness. The CDC's COVID vaccine guidance for pregnant women has been offline for months despite evidence linking infection to preterm births and neurological damage. This administration prioritizes grift over public health, with consequences spanning decades. SUPPORT & CONNECT WITH HAWK- Support on Patreon: https://www.patreon.com/mdg650hawk- Support Hawk's Merch Store: https://hawkmerchstore.com- Connect on TikTok: https://www.tiktok.com/@hawkeyewhackamole- Connect on BlueSky: https://bsky.app/profile/mdg650hawk.bsky.social- Connect on YouTube: https://www.youtube.com/@hawkpodcasts ALL HAWK PODCASTS INFO- Additional Podcasts Available Here: https://www.hawkpodcasts.com- Listen to Hawk Podcasts On Your Favorite Platform:Spotify: https://spoti.fi/3RWeJfyApple Podcasts: https://apple.co/422GDuLYouTube: https://youtube.com/@hawkpodcastsiHeartRadio: https://ihr.fm/47vVBdPPandora: https://bit.ly/48COaTBSimplecast: https://hawk-droppings.simplecast.com- Hawk Podcasts RSS Feed: https://feeds.simplecast.com/pPVtxSNJ

Description: Psoriatic disease affects far more than just the skin. Hear leading dermatologist Dr. April Armstrong and Dr. Benoît Guérrette discuss this and more with Jensen, a patient advocate. Psoriatic disease affects not only the skin but it can impact confidence, emotional and social well-being, and daily life. In this episode, join moderator Dr. Guy Eakin, Chief Scientific and Medical Officer at NPF, as we explore the disconnect between clinical classifications of psoriasis and what patients experience in real-life with leading dermatologist Dr. April Armstrong, Dr. Benoît Guérrette, Vice President of Dermatology & Rheumatology at Takeda, and Jensen, a NPF patient advocate and former Lead Youth Ambassador. Listen as we address the need for a more nuanced approach to classifying disease severity that accounts for the holistic needs of psoriatic disease, as well as share insights into how advocacy and awareness can drive change in treatment access and care standards.  The intent of this episode is to identify how clinical severity classifications of psoriasis are evolving to meet the needs of those who live with the disease and how that change impacts overall management. This episode is sponsored by Takeda. Timestamps: (0:00) Intro to Psoriasis Uncovered and guest welcome to dermatologist Dr. April Armstrong, Vice President of Takeda, Dr. Benoît Guérette, and patient advocate Jensen, who discuss the unmet needs of people with moderate psoriasis and how as a community we can better serve those living with the disease. 2:22 How health care providers and the biopharmaceutical industry are coming together to address systemic eligibility and the unmet needs of people living with psoriasis. 4:25 Quality of life should be included when assessing clinical severity in psoriasis and identification of appropriate treatment choices. 6:52 The impact of misdiagnosis, inappropriate treatment, and effect on high impact sites can be life- altering. 8:30 How appropriate treatment and knowledge can make all the difference when diagnosed with plaque psoriasis.  9:40 Views on the psoriasis disease classification system and how it's evolving to include real life impact from physical and emotional needs, to more personalized care for those living with psoriasis, even when small body surface areas are involved. Severity isn't defined by skin coverage alone. 12:38 What's needed to prioritize the care and outcomes of people living with psoriasis. 14:18  The future of management and care for psoriatic disease. 15:53  "My skin tells a story." Wisdom from what I wish I had known previously. 16:52  Moving closer to care that truly reflects the lives and needs of those who live with psoriasis. Key Takeaways: ·       Severity of psoriasis isn't defined by skin coverage or body surface area (BSA) alone. The impact on quality of life should also be considered in the assessment, selection of treatment, and management of the disease.  ·       The psoriasis disease classification system is evolving to be more of a patient centered approach.  Many clinicians are now using the International Psoriasis Council (IPC) or 2 bucket approach to identify whether someone should receive a topical or systemic treatment based on location and response to treatment, as well as impact on quality of life.  ·       With continued research and  development, the next 5 to 10 years could see a shift in effective treatment options while also treating sooner to initiate better outcomes for people living with psoriasis and psoriatic arthritis. Guest Bios:   April Armstrong, M.D., M.P.H. is an internationally renowned dermatologist and clinical researcher who is a Professor and Chief of Dermatology at the University of California Los Angeles (UCLA) where she specializes in inflammatory skin diseases such as psoriasis, atopic dermatitis, and hidradenitis suppurativa (HS). Dr. Armstrong is also the Co-Director for Network Resources at the UCLA Clinical and Translational Research Institute. She has conducted over 150 clinical trials and published over 350 high impact articles in scientific journals. Dr. Armstrong holds multiple leadership positions including the immediate Past Chair of the National Psoriasis Foundation Medical Board, Co-President of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), councilor for the International Psoriasis Council, and board member for the International Dermatology Outcome Measures and the American Academy of Dermatology.  Benoît Guérette, Ph.D. is an accomplished leader in medical affairs with extensive experience across academia and the pharmaceutical industry. Since March 2025, Dr. Guérette has served as Vice President of Dermatology and Rheumatology US Medical Affairs at Takeda Pharmaceutical. Prior to joining Takeda, he held several strategic and leadership roles at various pharmaceutical companies, including overseeing clinical development, global and U.S. medical affairs, global access & pricing, translational sciences and more. Before transitioning to the industry, Dr. Guérette was an Associate Professor of Immunology at Laval University, leading research in cancer immunology. He holds a Ph.D. in Medicine, Microbiology, and Immunology from Laval University and completed postdoctoral studies in Inflammation and Immunology at  Harvard Medical School.  Jensen is a volunteer and former Lead Youth Ambassador for the National Psoriasis Foundation. Jensen developed psoriasis at age 7 but wasn't formally diagnosed until age 14 being misdiagnosed along the way, trying different management approaches that were ineffective. She was a competitive swimmer from elementary through high school and in the last 2 years of high school played lacrosse. Upon finishing high school she attended college becoming a registered nurse in an intensive care unit. Jensen wants "youth living with psoriatic disease to feel a  community that is behind them and with them every step of the way. I really want to be able to make a difference in a way that would've helped me as a child when I was diagnosed." Resources: Ø  "Reassessing Psoriasis Severity" Advance Online, National Psoriasis Foundation. H. Onorati. January 16, 2024,  https://www.psoriasis.org/advance/psoriasis-severity-high-impact-sites/   Ø  "Psoriasis Involving Special Areas is Associated with Worse Quality of Life, Depression, and Limitations in the Ability to Participate in Social Roles and Activities". Blauvelt, A., Strober, B., Gondo, G., Journal of Psoriasis and Psoriatic Arthritis Volume 8, Issue 3.  https://journals.sagepub.com/doi/full/10.1177/24755303231160683

Guest: Dr. Anderson is currently the Albert H. Coons Professor of Neurology at Harvard Medical School, Senior Scientist at the Brigham and Women's Hospital, Institute Member of the Broad Institute of MIT and Harvard, and Core Faculty Member of the Gene Lay Institute of Immunology and Inflammation. She talks about her research on immune regulation in cancer and enhancing anti-tumor immunity. (38:33) Featured Products and Resources: Submit your abstract now for IMMUNOLOGY2026! Download a free wallchart on the production of CAR T cells. The Immunology Round Up CAR Tregs for Atherosclerosis: Anti-oxidized low-density lipoprotein CAR Tregs reduce atherosclerotic plaque formation in mouse models. (2:20) Tumor-Reactive T Cells: Tumor-reactive CD8+ T cells can be isolated and expanded from clinical samples. (14:24) Harnessing Myeloid and Lymphoid Synergy for Immunotherapy: Myeloid-targeted immunocytokines and natural killer/T cell enhancers show potential for treating solid cancers. (18:50) Subcutaneous Fat Affects Intestinal Aging: Subcutaneous white adipose tissue dysfunction triggers aging-like intestinal dysfunctions in mouse models. (32:40) Subscribe to our newsletter! Never miss updates about new episodes. Subscribe

On this episode: Lucy Lopez, Elizabeth Newcamp, and Zak Rosen are handing the show over to Slate's news podcast, What Next.  Thousands of children may be avoiding peanut allergies thanks to research indicating that early exposure to—rather than avoidance of—the legume is key. Now there's reason to believe this is true for tons of allergens – and that the great “pandemic” of kid food allergies never needed to happen. Guest:  Dr. David Hill, attending physician with the Division of Allergy and Immunology at Children's Hospital of Philadelphia, and The Hill Lab. Want more What Next? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and across all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now atslate.com/whatnextplus to get access wherever you listen. Podcast production by Elena Schwartz, Paige Osburn, Anna Phillips, Madeline Ducharme, and Rob Gunther. Learn more about your ad choices. Visit megaphone.fm/adchoices

On this episode: Lucy Lopez, Elizabeth Newcamp, and Zak Rosen are handing the show over to Slate's news podcast, What Next.  Thousands of children may be avoiding peanut allergies thanks to research indicating that early exposure to—rather than avoidance of—the legume is key. Now there's reason to believe this is true for tons of allergens – and that the great “pandemic” of kid food allergies never needed to happen. Guest:  Dr. David Hill, attending physician with the Division of Allergy and Immunology at Children's Hospital of Philadelphia, and The Hill Lab. Want more What Next? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and across all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now atslate.com/whatnextplus to get access wherever you listen. Podcast production by Elena Schwartz, Paige Osburn, Anna Phillips, Madeline Ducharme, and Rob Gunther. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Christmas season brings with it lots of merrymaking and in spite of less drinking happening overall and the availability of many zero alcohol products, many of us will be getting drunk. And soon afterwards, many of us will regret it. Surely the answer is simple: to avoid a hangover, just drink less? Alas, that is easier said than done. Alcohol's inhibition-reducing effects can undermine the steeliest resolve.All to discuss with Professor Luke O Neill , Professor of Biochemistry at the school of Immunology, Trinity College.

Mehlman Qbanks: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://qbanks.mehlmanmedical.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠IG: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/mehlman_medical/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Telegram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://mehlmanmedical.com/subscribe/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

ReferencesEuropean Journal of Immunology 2011. NOV. 41(11):3114-24European Journal of Immunology1996 V. 26, Issue 8Nature . 2024 Oct;634(8034):729-736 Proc Natl Acad Sci U S A .1986 Mar;83(6):1852-6.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of significant stories shaping the future of healthcare, from innovative financing strategies to groundbreaking scientific advancements.The biotech industry in 2025 has experienced a notable shift in funding strategies, particularly through the rising trend of royalty financing. This approach, involving the exchange of future drug revenue for immediate capital, has surged to approximately $3.5 billion in disclosed upfront volume in just the first half of the year. According to health economist Julien Willard, this represents a transformative shift from a niche option to a mainstream strategy amid challenging equity and credit markets. Royalty financing provides biotech companies with a lifeline, allowing them to avoid the pitfalls of equity dilution or high-interest debt while retaining control over their clinical developments. Firms like Royalty Pharma and Healthcare Royalty Partners are at the forefront, offering upfront cash for future sales royalties, typically ranging from 2.5% to 7.5%.This trend has accelerated due to economic pressures like low stock valuations and rising interest rates, making traditional funding routes less viable. A closer look at this year's deals reveals a cautious approach among investors, who are focusing on phase 3 trials or candidates awaiting FDA approval rather than early-stage assets. Oncology takes center stage as the leading therapeutic area, accounting for about 70% of total disclosed funding, thanks to its potential for large revenue streams. Other areas like rare genetic diseases and immunology also attract significant attention.Interestingly, even large pharmaceutical companies such as Biogen have ventured into royalty financing—an unconventional move for well-capitalized firms. Biogen's collaboration with Royalty Pharma for lupus drug development illustrates innovative financial engineering by transferring clinical trial risk through milestone-tied payments. As this strategy gains traction globally, especially in cash-strapped regions like Asia, it serves as a crucial tool for companies prioritizing survival and continued innovation amidst financial uncertainties.Turning now to regulatory dynamics and strategic shifts within the industry. The legal controversy between GSK's subsidiary Tesaro and AnaptysBio over Jemperli highlights complexities in collaborative agreements within drug development. Such disputes could reshape how companies negotiate intellectual property rights and revenue sharing in future co-development deals.The FDA's investigation into Takeda's Adzynma following a pediatric patient's death underscores the critical role of post-market surveillance in drug safety. This incident could potentially impact Takeda's market position while emphasizing the need for robust adverse event monitoring systems across biopharmaceutical firms.In Australia, the government's decision to block Cosette's proposed $430 million acquisition of Mayne Pharma reflects increasing scrutiny on foreign investments in healthcare companies, prioritizing national interest. This move signals a growing trend that could reshape global M&A strategies within the sector.Meanwhile, Moderna's strategic financial maneuvering is noteworthy. By securing a $1.5 billion loan aimed at supporting its commercial and R&D endeavors with an eye on breaking even by 2028, Moderna demonstrates its commitment to diversifying its mRNA technology applications beyond COVID-19 vaccines—a move likely to influence innovation trajectories across biotech landscapes. Additionally, Moderna's decision to discontinue three clinical mRNA programs showcases strategic pipeline management amidSupport the show

A recent study from the Massachusetts Institute of Technology in the US suggests that using AI makes students less smart. Pat discuss these findings with Professor Luke O Neill , Professor of Biochemistry at the school of Immunology, Trinity College.

 In this episode, Sakara founders Whitney Tingle and Danielle DuBoise sit down with world-renowned fertility expert Dr. Zaher Merhi, founder and medical director of the Rejuvenating Fertility Center. Named one of the Top 2% Scientists in the World, Dr. Merhi is pioneering a new era of women's health—one where fertility, longevity, and regenerative medicine are deeply interconnected. Together, they explore groundbreaking new frontiers in fertility—from stem cell ovarian rejuvenation and reproductive immunology to natural and low-dose IVF alternatives. Dr. Merhi challenges traditional fertility medicine, emphasizing that IVF isn't always the answer—and that many women can restore fertility and hormonal health by addressing underlying inflammation, immune imbalances, and lifestyle factors. Whether you're thinking about kids, navigating perimenopause, or simply curious about optimizing your hormonal health, this conversation offers a powerful perspective: your fertility is a reflection of your overall vitality—and supporting it means nurturing your whole body, mind, and spirit. Dr. Merhi Shares:  Why inflammation is at the root of many fertility challenges How reproductive immunology helps prevent miscarriage and support healthy pregnancies The science of PRP and stem cell ovarian rejuvenation Why IVF is not the only answer The link between mental state, nourishment, and fertility How regenerative therapies like ozone and exosome treatments are advancing longevity and hormonal health Check out the video version on the Sakara Life YouTube channel here: https://youtu.be/uTjlwH7wNhM  About Dr. Merhi: Dr. Merhi is the founder and the medical director of Rejuvenating Fertility Center (RFC). He is an internationally recognized fertility doctor, lecturer, editor, and grant reviewer. His training and faculty appointments included Albert Einstein College of Medicine/Montefiore Medical Center, NYU School of Medicine, and University of Vermont. He was a Professor at SUNY Downstate Health Sciences University and the Director of the Reproductive Endocrinology and Infertility (REI) Fellowship program (ACGME accredited). He is currently a Professor at Albert Einstein College of Medicine and Maimonides Medical Center in New York. He has 3 American Board certifications in OB/GYN, Reproductive Endocrinology and Infertility, and High-Complexity Laboratory Director (HCLD). Dr. Merhi is one of the few Reproductive Immunologists in the country and is an active researcher with an interest in women older than 40 with Low Ovarian Reserve (low AMH or high FSH), Stem Cell ovarian rejuvenation, gentle stimulation IVF, natural IVF, and IVF without injectables. He was named “Top 2% Scientists in the World.”His research also focuses on technologies, such as Stem Cell Exosomes, Ozone Sauna therapy, and Low Level Laser Therapy (LLLT), that could improve egg quality especially in women with endometriosis, immune disorders, and PCOS. Dr. Merhi is also experienced in treating overweight women and those who had weight loss surgery. He is a strong proponent of the LGBTQ+ community and has proudly served the Arabic and Jewish Communities for over two decades.

We're re-releasing one of our most popular episodes, an important conversation with Wolfram syndrome expert Dr. Fumi Urano.   We're bringing this episode back in honor of Diabetic Eye Disease Month, and because it's the perfect follow-up to our last episode featuring Dr. Rachel Hyman and our very own co-host Cathy Gildenhorn as guests. Their experiences with the milder, adult-onset variant of Wolfram syndrome sparked so much interest, we knew this episode needed another moment in the spotlight. You'll hear Cathy interview Dr. Urano, her lead physician, about symptoms, diagnosis, and promising research underway to help people with rare neurodegenerative disorders like Wolfram syndrome.   We are thrilled to have Dr. Fumihiko Urano on “It Happened To Me” as he is our co-host Cathy's lead doctor, for her variant of the rare disease, Wolfram Syndrome.    Fumihiko “Fumi” Urano, MD, Ph.D., is a Physician and Medical Researcher specializing in Wolfram syndrome, characterized by juvenile-onset diabetes, vision loss, and neurodegeneration. Dr. Urano is a Professor of Medicine and Pathology & Immunology, an attending physician at Endocrinology Genetics Clinic, and currently holds Samuel E. Schechter Endowed Professorship in Medicine at Washington University Medical Center, St. Louis, USA. Dr. Urano is a driving force in the study of Wolfram syndrome and Related Disorders, including WFS1-related disorders/Wolfram-like disorders. As the Director of the Wolfram Syndrome and Related Disorders Clinic and Study at Washington University Medical Center, Dr. Urano has been leading the clinical, translational, and interventional studies of Wolfram syndrome and Related disorders. Dr. Urano's collaboration with colleagues at the medical center and around the world has allowed him to develop cutting-edge treatments for this disease, including gene therapy and regenerative therapy.    Learn more on their Wolfram syndrome website, wolframsyndrome.wustl.edu. If you want to reach out directly you can contact the Research Nurse Coordinator Stacy Hurst, RN, CDE by calling 314-747-3294 or emailing shurst@wustl.edu.    During the episode Dr. Urano mentioned two episodes of “It Happened To Me”: during this episode. The first was our interview with Dr. Gladstone in Episode 5. He also gave a shoutout to our conversation with Stephanie Snow Gebel (Snow Foundation) in Episode 9.    Stay tuned for the next new episode of “It Happened To Me”! In the meantime, you can listen to our previous episodes on Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “It Happened To Me”.    “It Happened To Me” is created and hosted by Cathy Gildenhorn and Beth Glassman. DNA Today's Kira Dineen is our executive producer and marketing lead. Amanda Andreoli is our associate producer. Ashlyn Enokian is our graphic designer.   See what else we are up to on Twitter, Instagram, Facebook, YouTube and our website, ItHappenedToMePod.com. Questions/inquiries can be sent to ItHappenedToMePod@gmail.com.

Earlier this month, more than 2,500 allergists and healthcare professionals gathered in Orlando, Florida, for the annual meeting of the American College of Allergy, Asthma & Immunology—better known as ACAAI. It's one of the biggest events of the year where experts share the latest research, treatments, and guidelines in allergy and immunology. We're thrilled to be joined by this year's keynote speaker, program chair—and FAACT Medical Board Member—Dr. Kristin Sokol, MD, MS, MPH, who shares highlights and key takeaways from this cutting-edge meeting.Resources to keep you in the know:American College of Allergy Asthma and Immunology (ACAAI)Schreiber Allergy: Kristin Sokol, M.D., MS, MPH, FACAAI, FAAAAIYou can find FAACT's Roundtable Podcast on Apple Podcasts, Pandora, Spotify, Podbay, iHeart Radio, or wherever you listen to podcasts.Follow us on Facebook, Instagram, BlueSky, Threads, LinkedIn, Pinterest, TikTok, and YouTube.Sponsored by: GenentechThanks for listening! FAACT invites you to discover more exciting food allergy resources at FoodAllergyAwareness.org!

Today, on the Egg Whisperer Show podcast, I'm excited to be joined by Dr. Andrea Vidali. He is a world renowned endometriosis specialist, surgeon, miscarriage specialist and reproductive immunologist. Dr. Vidali is the founder and CEO of Pregmune, a healthcare information company that leverages his research in the fields of IVF and its relation to miscarriage and Immunology. I'm delighted to have him join us to talk about Pregmune and the role immunological factors play in fertility. In today's interview, we are going to be talking about what fertility patients need to know about immunological factors, how immunological factors may present themselves when diagnosed with "unexplained infertility," 6 important factors that may impact your ability to conceive, and how to get tested in order to see if any immunological factors may be involved when having difficulty conceiving.   Read the full show notes on Dr, Aimee's website. Tune in to the Egg Whisperer Show here. You can find Dr. Vidali at his website, here. Do you have questions about IVF, and what to expect? Click here to join Dr. Aimee for The IVF Class. The next live class call is on Monday, November 17, 2025 at 4pm PST, where Dr. Aimee will explain IVF and there will be time to ask her your questions live on Zoom.   Dr. Aimee Eyvazzadeh is one of America's most well known fertility doctors. Her success rate at baby-making is what gives future parents hope when all hope is lost. She pioneered the TUSHY Method and BALLS Method to decrease your time to pregnancy. Learn more about the TUSHY Method and find a wealth of fertility resources at www.draimee.org  where you can schedule a consultation. Other places to find The Egg Whisperer: Click to find The Egg Whisperer Show podcast on your favorite podcasting app. Watch videos of Dr. Aimee answer Ask the Egg Whisperer Questions on YouTube.Sign up for The Egg Whisperer newsletter to get updates

The appetite for weight-loss drugs, known as glp-1 agonists, has been insatiable since they hit the market a decade ago. In 2024 global spending on them reached $54bn, a figure that is sure to rise in the coming years. As pharmaceutical firms elbow each other for a slice of the pie, the number of options will grow in 2026 All to discuss with Professor Luke O Neill , Professor of Biochemistry at the school of Immunology, Trinity College.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In today's rapidly evolving landscape, we witness significant strides shaping the future of drug development, patient care, and global market dynamics.Merck & Co. has made a notable advancement in cholesterol management with a PCSK9-targeted pill. This pill has achieved reductions in low-density lipoprotein cholesterol (LDL-C) comparable to existing injectable therapies. Such innovation represents a significant step forward by potentially offering a more convenient oral alternative for patients. The development underscores the industry's ongoing efforts to enhance patient compliance and therapeutic outcomes through novel drug delivery mechanisms.In a strategic corporate move, Pfizer has successfully acquired Metsera, an obesity biotech company, for a substantial $10 billion. This acquisition, which followed an intense bidding war with Novo Nordisk, exemplifies Pfizer's aggressive expansion in the obesity treatment market—a growing global health challenge. The strategic buyout positions Pfizer to leverage Metsera's expertise, potentially accelerating the development and commercialization of innovative obesity treatments.Meanwhile, Novo Nordisk is enhancing its presence in India by partnering with Emcure Pharmaceuticals to expand access to Wegovy, its weight-loss treatment. This collaboration is particularly significant given India's escalating obesity rates and highlights the importance of regional partnerships in enhancing drug accessibility and addressing public health issues.Regulatory developments continue to influence industry dynamics as well. The FDA has postponed its decision on expanding Rhythm Pharmaceuticals' Imcivree for additional indications. These regulatory delays highlight the complexities and unpredictabilities inherent in drug approval processes, underscoring the need for companies to strategically navigate these challenges.Regeneron and AstraZeneca have reported clinical trial successes with their respective anti-inflammatory drugs, Dupixent and Fasenra. These positive outcomes were showcased at the American College of Allergy, Asthma, and Immunology's annual meeting, bolstering the companies' aspirations for FDA approvals. Successful clinical outcomes not only pave the way for expanded therapeutic options but also demonstrate the industry's commitment to addressing complex inflammatory conditions.October has seen a surge in TV advertising spending, led by Johnson & Johnson's campaign for Tremfya. The campaign highlights the power of patient community engagement in bringing attention to conditions like inflammatory bowel disease (IBD), emphasizing how patient advocacy can reduce isolation among sufferers.In oncology, Cogent Biosciences is on track for an FDA submission following successful phase 3 trials of its cancer asset bezuclastinib. This development illustrates the critical role of rigorous clinical research in advancing oncology treatments and potentially improving patient outcomes.Turning our attention to technological frontiers within pharmaceutical R&D, Eli Lilly has been particularly active in cementing its commitment to artificial intelligence (AI) and gene therapy through several strategic collaborations. The company has entered into a $100 million-plus research agreement with Insilico Medicine to leverage AI for drug discovery. This partnership aims to expedite the identification of novel therapeutic targets and enhance drug development efficiency—a reflection of a broader industry trend towards integrating AI into pharmaceutical processes.Additionally, Lilly has made a notable move in gene therapy by acquiring rights from MeiraGTx for a retinal disease therapy that has shown Support the show

Kingston Mills, Professor of Experimental Immunology, School of Biochemistry and Immunology at TCD

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative events reshaping the landscape of healthcare, from strategic mergers and regulatory shifts to groundbreaking advancements in drug development.Let's begin with a monumental merger that signals a shift towards more integrated healthcare solutions. The $48.7 billion acquisition of Kenvue, a consumer health spinout from Johnson & Johnson, by Kimberly-Clark illustrates the growing convergence between consumer health products and traditional pharmaceuticals. This strategic move highlights a trend towards expanding product portfolios and enhancing distribution networks, aiming to better address comprehensive patient needs. Mergers like these could redefine how healthcare products are marketed and delivered, emphasizing holistic approaches to patient care.Turning to regulatory news, the resignation of Dr. George Tidmarsh from the FDA due to controversial communications has spotlighted the ongoing challenges within regulatory oversight. This incident underscores the delicate balance regulators must maintain in ensuring transparency while safeguarding sensitive information. Such developments are crucial as they directly affect public trust in drug approval processes and the industry's ability to navigate complex regulatory landscapes.In scientific advancements, Roche is making significant progress with its drug Gazyva for autoimmune diseases. Following FDA approval for lupus-related kidney disease, promising Phase 3 trial results for systemic lupus erythematosus (SLE) are propelling Roche closer to offering new hope for patients with this chronic condition, which currently has limited effective treatments. This success underscores the potential of targeted therapies in transforming treatment paradigms for autoimmune diseases.Eli Lilly's $3 billion investment in a new manufacturing facility in the Netherlands marks a strategic effort to bolster oral medicine production globally. This expansion not only reinforces Lilly's commitment to meeting global demand but also reflects an industry-wide trend towards investing in scalable manufacturing capabilities. Such moves are critical for ensuring supply chain resilience and addressing rising healthcare needs worldwide.In legal news, Pfizer's fierce competition with Metsera over Novo Nordisk's counteroffer highlights the high stakes involved in securing promising assets within the biotech sector—a sector particularly focused on obesity treatment due to its substantial market growth potential. The outcome of this legal battle could influence future strategic partnerships and acquisitions, demonstrating the intense competition among pharmaceutical giants.Meanwhile, UniQure faces challenges as its gene therapy for Huntington's disease encounters regulatory hurdles with the FDA. Despite initial expectations as a groundbreaking treatment, this setback emphasizes the rigorous scrutiny gene therapies undergo to ensure safety and efficacy. Such hurdles highlight the complexities of advancing novel therapies through regulatory pathways.Policy developments are also reshaping drug pricing structures as evidenced by HRSA's approval of eight drugmakers' plans for a 340B rebate model pilot program. This initiative aims at optimizing pricing structures while balancing cost containment with access to essential medications for underserved populations—a critical concern in today's healthcare landscape.International collaborations continue to play a pivotal role in accelerating drug discovery and development. Neurocrine Biosciences' $880 million deal with China's TransThera Sciences exemplifies such partnerships, focusing on emerging therapeutic areas like immunology. These collaborations are vital in leveraging global expertise and resources to drive innovatSupport the show

In this episode of the Healthy & Awake Podcast, Mike Vera talks with immunotoxicologist Dori Smith, who reversed seven autoimmune diseases after being disabled for over a decade. They dive into the root causes of chronic inflammation, the science behind detoxification, and how functional medicine can help the body heal naturally. Dori shares how understanding genetics, nutrition, toxins, and faith transformed her life—and why conventional medicine still overlooks these key insights. If you've ever wondered whether true recovery from chronic illness is possible, this conversation will change your perspective.

“At some point, feeling good wins over old thoughts.” –VJ HamiltonStruggling with autoimmune disease — or uncomfortable symptoms that you've just learned to live with? What if you could reverse your symptoms? I'm so excited to talk with VJ Hamilton, registered nutritionist and a functional medicine practitioner who specializes in autoimmune disease.I was diagnosed with celiac disease fairly late in life. When I was diagnosed, it just made so much sense and explained so many things. It also led to change. And that can be hard to navigate on your own.Perimenopause and menopause symptoms and those of autoimmune diseases — like brain fog, joint aches, and fatigue — can be signs of both. Plus shifts in hormones can certainly trigger changes or unmask hidden inflammation. Testing and treatment can help.We talk about: Autoimmune disease 101 — what we're actually talking aboutTriggers vs. root causes and how to find the root causeHow to advocate for yourself with doctors and what other practitioner you might want to seeSimple changes you can make to improve your healthFocus not on what you have to cut out for food or what exercise you have to do, but what you need and what you likeEating whole foods instead of prepared meals and how to navigate restaurants and special eventsABOUT VJVJ Hamilton is the founder of The Autoimmunity Nutritionist and an expert in autoimmune disease, specialising in skin disorders, chronic fatigue, joint health, and digestive issues for both men and women.As a Registered Nutritionist with a Medical Science degree (BSc) in Biochemistry & Immunology and having completed the full certification programme at the renowned Institute for Functional Medicine, VJ uses evidence-based nutritional therapies to support her clients in transforming their health.LINKShttps://theautoimmunitynutritionist.com/https://www.instagram.com/theautoimmunitynutritionist/ https://www.linkedin.com/in/theautoimmunitynutritionist/ DOABLE CHANGESAt the end of every episode, we share three doable changes, so you can take what you've heard and put it into action. Action is where change happens. But here's the thing: when we have a goal, a wish, a desire bubbling up in us, it can feel really huge. Sometimes we stop ourselves in our tracks based on how huge our desire feels. Change needs action, but it doesn't need huge action. When we focus on the next step, the next Doable Change that we can integrate into our lives, we don't get stuck and we create momentum. Choose one Doable Change that resonates with you today and really play with it. Fit it into your life, your days, make it work for you — then move on to your next Doable Change. Here are Three Doable Changes from this conversation: MAKE A LIST OF THINGS YOU LOVE TO DO. Changing your lifestyle doesn't have to be terrible! Make a list of things you love to do. Ways you like to be active, rest, connect with others. Make a list of things that make you feel good! Plan for more of those things in your life. That might look like swapping dancing for a gym session or eating food that gives you energy or going to bed on time.RESET IDEAS AROUND FOOD. Here are a few ways to try this Doable Change. First, instead of asking, “What do I have to cut out?” think about what foods you can...

Thousands of children may be avoiding peanut allergies thanks to research indicating that early exposure to—rather than avoidance of—the legume is key. Now there's reason to believe this is true for tons of allergens – and that the great “pandemic” of kid food allergies never needed to happen. Guest:  Dr. David Hill, attending physician with the Division of Allergy and Immunology at Children's Hospital of Philadelphia, and The Hill Lab. Want more What Next? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and across all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now at slate.com/whatnextplus to get access wherever you listen. Podcast production by Elena Schwartz, Paige Osburn, Anna Phillips, Madeline Ducharme, and Rob Gunther. Learn more about your ad choices. Visit megaphone.fm/adchoices

Thousands of children may be avoiding peanut allergies thanks to research indicating that early exposure to—rather than avoidance of—the legume is key. Now there's reason to believe this is true for tons of allergens – and that the great “pandemic” of kid food allergies never needed to happen. Guest:  Dr. David Hill, attending physician with the Division of Allergy and Immunology at Children's Hospital of Philadelphia, and The Hill Lab. Want more What Next? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and across all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now at slate.com/whatnextplus to get access wherever you listen. Podcast production by Elena Schwartz, Paige Osburn, Anna Phillips, Madeline Ducharme, and Rob Gunther. Learn more about your ad choices. Visit megaphone.fm/adchoices

Thousands of children may be avoiding peanut allergies thanks to research indicating that early exposure to—rather than avoidance of—the legume is key. Now there's reason to believe this is true for tons of allergens – and that the great “pandemic” of kid food allergies never needed to happen. Guest:  Dr. David Hill, attending physician with the Division of Allergy and Immunology at Children's Hospital of Philadelphia, and The Hill Lab. Want more What Next? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and across all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now at slate.com/whatnextplus to get access wherever you listen. Podcast production by Elena Schwartz, Paige Osburn, Anna Phillips, Madeline Ducharme, and Rob Gunther. Learn more about your ad choices. Visit megaphone.fm/adchoices

In today's episode, we had the pleasure of speaking with Eunice Wang, MD, about the secondary AML treatment paradigm. Dr Wang is a professor of oncology, leader of the Leukemia Clinical Disease Team, chief of leukemia in the Department of Medicine, and an assistant member of the Tumor Immunology Program in the Department of Immunology at Roswell Park Comprehensive Cancer Center in Buffalo, New York; as well as an associate professor in the Department of Medicine and an academic scholar at the Jacobs School of Medicine and Biomedical Sciences at the State University of New York at Buffalo. In our exclusive interview, Dr Wang discussed the prevalence of secondary AML, and explained that this population lacks standard therapies, often relying on allogeneic stem cell transplantation. She noted that CPX-351, a liposomal formulation of cytarabine and daunorubicin, has generated improved outcomes compared with 7+3 chemotherapy in this population. She also highlighted future research, which includes targeted therapies and less intensive regimens.

In this episode of SHE MD Podcast, Dr. Thaïs Aliabadi and Mary Alice Haney sit down with Dr. Tania Elliott to discuss allergies, immune health, and how hormonal changes impact symptoms. They explore practical strategies to reduce allergy triggers at home, boost immune health naturally, and adopt a personalized approach to allergy care. Dr. Elliott shares insights on seasonal allergies, food allergies, and hidden allergens in daily life, while providing actionable guidance for women navigating hormonal shifts during pregnancy, menopause, or with birth control. Listen to gain evidence-based tips to improve overall health, enhance quality of life, and take control of their wellness journey. Subscribe to SHE MD Podcast for expert tips on PCOS, Endometriosis, fertility, and hormonal balance. Share with friends and visit SHE MD Podcast and Ovii for research-backed resources, holistic health strategies, and expert guidance on women's health and well-being.Sponsors:Saje: Visit Saje.com to purchase plant powered products to remedy your needs. Use Code ‘SHEMD' for 20% off sitewide and free shippingOpill: Opill is birth control in your control, and you can use code SHEMD for twenty five percent off your first month of Opill at Opill.com.iRestore: For a limited time, get a HUGE discount on the iRESTORE Elite + Illumina Face Mask Bundle with code SHEMD at iRestore.comMerit: It's time to simplify your morning (Alt: Ready to simplify your routine?). Head to meritbeauty.com and get their Signature Makeup Bag free with your first order.Peloton: Let yourself run, lift, sculpt, push, and go. Explore the new Peloton Cross Training Tread+ at onepeloton.comGetJoy: As a listener of SheMD, you'll get 50% off your first subscription order of Get Joy's Freeze Dried Raw Dog Food plus two exclusive gifts: a free scoop and a 4oz bag of treats. Shop getjoyfood.com/shemd to support your dog's gut health and overall wellnessProlon: For a limited time, you can be first in line to experience the new Next Gen at special savings. Prolon is offering SHE MD listeners 15% off sitewide plus a $40 bonus gift when you subscribe to their 5-Day Program!Cymbiotika: Go to Cymbiotika.com/Shemd for 20% off plus free shippingWhat You'll LearnUnderstanding how seasonal allergies, food allergies, and intolerances differHow hormonal changes impact allergy symptoms in womenStrategies to reduce allergy triggers at home and boost immune health naturallyWhen to use at-home allergy tests safely versus consulting a professionalKey Timestamps(02:42) Dr. Tania Elliott's Introduction (05:23) Dr. Elliott's journey in allergy and immunology(08:45) Common myths about allergies and immune health(13:10) Actionable tips: reducing triggers, hormonal considerations, lifestyle adjustments(22:24) Understanding seasonal vs. food allergies and intolerances(28:05) Hormonal shifts affecting immune system and allergies in women(35:58) Microplastics and toxins(49:29) Top 3 lifestyle changes to reduce allergens and improve healthKey Takeaways Seasonal allergies, food allergies, and intolerances affect women differently, especially during hormonal changesHidden allergens in everyday life can trigger reactions without noticeLifestyle factors like sleep, stress, and gut health influence immune resiliencePersonalized allergy care is more effective than one-size-fits-all approachesAt-home allergy tests can be helpful but professional guidance is essential for accurate diagnosisGuest BioDr. Tania Elliott is a dual board-certified physician specializing in Internal Medicine and Allergy/Immunology. She serves as a Clinical Instructor at NYU Langone Health and is a spokesperson for the American College of Allergy, Asthma, and Immunology. Dr. Elliott empowers people to take control of their health through actionable advice and personalized care. She is also the founder of Modern Medical, a consulting firm providing strategic support across healthcare sectors.Links:

Professor Matteo Iannacone is Director of the Division of Immunology, Transplantation and Infectious Diseases, Professor of Pathology, and Head of the Dynamics of Immune Responses laboratory at Vita-Salute San Raffaele University. His work centers on understanding the generation of dysfunctional adaptive immune cells in chronic hepatitis B virus infection and developing new strategies to reprogram them into functional cells endowed with potent antiviral activity.

In the world of social media memes, madness and mayhem, the claim "I've done my research" is usually a euphemism for the far more accurate "I read, heard or watched something on the internet." In this TYP instalment, Professor Bill and I chat about the recent media hysteria around an alleged link between Tylenol (paracetamol in Australia) and autism. And while l'm no expert, it's fair to say that the bloke who's both a Professor of Pharmacology and Toxicology and a Professor of Microbiology and Immunology at Indiana University School of Medicine (The Prof.) is more medically informed and qualified to comment than most. So he did. And I listened. Enjoy.See omnystudio.com/listener for privacy information.

We end the futile struggle, embrace the toxins, and become one with our mould brethren.The full episode is available to Patreon subscribers (2 hours, 38 minutes).Join us at: https://www.patreon.com/DecodingTheGurusSupplementary Material 3800:00 Intro02:54 Boomer Matt reacts to Twitter videos07:31 Shellenberger and Tucker discuss the 9/11 Files12:42 Eric's Google Ngram Investigations17:08 Vindication on the Elephant Graveyard22:00 Eric's ARC lecture goes viral25:24 Andrew Huberman is NOT a phrenologist...29:06 Eric Weinstein vs. Piers Morgan33:44 Everyone knows Eric is a serious thinker46:09 Peterson is taken out of the Gurusphere by Demons and Toxic Mould52:09 Gurus and Bespoke Alternative Health57:00 Social Contagion Hypocrisy01:02:55 Toxic Mould Symbiosis?01:04:46 Pewdiepie, Diogenes, and the Seeker Mindset01:16:14 The Wisdom of the Ancients01:21:01 The Meaning Crisis and Christian Pivots01:22:29 Konstantin Kisin's surprising Christian pivot01:25:17 The best person Konstantin ever met (not Francis)01:30:22 The Fifth Column Agrees with Megyn Kelly 88% of the time01:33:07 Megyn Kelly explains how the Democrats crossed the line and must pay01:41:35 Intellectual Clerics for MAGA01:43:16 Slightly Adversarial libertarians for hire01:47:00 Drew Pavlou and Fluid Populism01:50:17 Two Varieties of Online Derangement: Noah Smith's Hot Takes01:53:57 Need for Attention = Desire for Virality01:57:23 Status Seeking Networkers vs Paul Bloom02:01:27 Reflecting on the Al Murray Interview02:02:22 The struggle of podcasters02:04:52 Paul Bloom: The best person in the world?02:06:00 Mike Israetel's Thesis Controversy02:10:30 What does a PhD mean?02:16:55 David Deutsch visits Curt Jaimungal02:22:32 The Dangers of Doubling Down: Pirate Software02:23:32 Hasan Piker and Shock Collar-gate02:27:15 Matt's Take on Shock Collars02:33:51 Dystopia Update: Putin wants Trump to win the Nobel Prize02:37:11 OutroSourcesShellenberger and Tucker discuss the CIA's role in 9/11Grok pressing Eric to get specificThe Elephant GraveyardViral post about Eric's ARC speech on scienceHuberman's phrenology endorsementJordan Peterson's Health Update from MikhailaChris Williamson: It's time to talk about my health.Chang, C., & Gershwin, M. E. (2019). The myth of mycotoxins and mold injury. Clinical Reviews in Allergy & Immunology, 57(3), 449–455.Borchers, A. T., Chang, C., & Eric Gershwin, M. (2017). Mold and human health: A reality check. Clinical Reviews in Allergy & Immunology, 52(3), 305–322.

Cindy sits down with Bali Pulendran at the AAI 2025 meeting where he told the story of how a childhood fascination with the cosmos grew into a career addressing fundamental questions about the human immune response, and how when an antigen enters the body it is like the big bang in how it initiates immune responses. Host: Cindy Leifer Guest: Bali Pulendran Subscribe (free): Apple Podcasts, RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server Systems vaccinology determines antibody responses and durability (Nature 2025) World's largest immunology experiment (Sem Immunol 2024) Systems Vaccinology Review (Immunity 2010) Time stamps by Jolene Ramsey. Thanks! Music by Tatami. Logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv Information on this podcast should not be construed as medical advice.

AI is transforming medicine at a speed never seen before. In this episode, you'll discover how digital twins and artificial intelligence will revolutionize drug discovery, eliminate human trials, and personalize your biology for longevity and high performance. Host Dave Asprey breaks down how AI can now simulate virtual cells and tissues, running clinical experiments in minutes instead of years to create truly individualized medicine. Watch this episode on YouTube for the full video experience: https://www.youtube.com/@DaveAspreyBPR Dr. Derya Unutmaz is a world-renowned immunologist, systems biologist, and professor at The Jackson Laboratory. With more than 150 scientific papers, he's a leading expert in immune system research and one of the first scientists to pioneer the concept of digital twins for biology. His groundbreaking work uses AI to model how immunity, metabolism, and aging interact—creating new possibilities for personalized medicine, disease prevention, and lifespan extension. Host Dave Asprey and Dr. Unutmaz reveal how AGI will soon outperform doctors, accelerate functional medicine, and optimize human biology far beyond today's standards. You'll learn how the immune system drives inflammation and aging, how to re-engineer it for resilience, and why compounds like GLP-1 and metformin may add years to your life. You'll Learn: • How digital twins will end human drug testing • Why AGI could replace doctors and computer jobs within five years • How AI models immune function, metabolism, and aging • The role of mitochondria and inflammation in longevity • How GLP-1 drugs and metformin extend lifespan • What continuous biological monitoring means for health tracking • How AI is transforming functional medicine and personalized care • Why NAD and energy metabolism are key to human performance They explore how artificial intelligence, biohacking, and systems biology intersect to create a smarter approach to health and longevity. You'll also learn how understanding immune balance, metabolism, and mitochondrial function helps build resilience and extend your lifespan. This is essential listening for anyone serious about biohacking, hacking human performance, and extending longevity through personalized medicine, functional biology, and cutting-edge AI innovation. This is essential listening for anyone serious about biohacking, hacking human performance, improving mobility, and extending longevity. You'll also learn how neuroplasticity, metabolism, and brain optimization all connect to the way you move. Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights in health, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence, and conscious living. New episodes are released every Tuesday, Thursday, Friday, and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: AI medicine, Digital twins, Functional medicine, Biohacking, Longevity, Immune system, Inflammation, Personalized medicine, GLP-1 therapy, Metformin, NAD boosters, Mitochondrial function, Metabolism, AGI, Clinical trials, Human performance, Aging research, Systems biology, Immunology, Smarter Not Harder Thank you to our sponsors! BrainTap | Go to http://braintap.com/dave to get $100 off the BrainTap Power Bundle. MASA Chips | Go to https://www.masachips.com/DAVEASPREY and use code DAVEASPREY for 25% off your first order. Our Place | Head to https://fromourplace.com/ and use the code DAVE for 10% off your order. ARMRA | Go to https://tryarmra.com/ and use the code DAVE to get 15% off your first order Resources: • Keep up with Derya's work: https://x.com/derya_?lang=en • Business of Biohacking Summit | Register to attend October 20-23 in Austin, TX https://businessofbiohacking.com/ • Danger Coffee: https://dangercoffee.com/discount/dave15 • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Upgrade Collective: https://www.ourupgradecollective.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen: https://40yearsofzen.com Timestamps: 00:00 — Trailer 01:25 — Intro 02:26 — AI's Role in Extending Lifespan 02:56 — Regulatory Frameworks and Medical Adoption 05:19 — Problems with the Immune System 08:19 — Chronic Fatigue and Long COVID Research 10:32 — Modern Testing and Multi-Omic Analysis 14:07 — Personal Longevity Strategy and Supplements 15:17 — Understanding Exhausted Cells 23:43 — Personalization in Medicine and AI Analysis 31:35 — Longevity Escape Velocity 36:13 — AI Doctors and Prescriptions 39:55 — Data Quality Concerns in AI Training 43:19 — The Future of Wearable Technology 45:50 — Revolutionizing Education with AI 49:04 — The Future of Higher Education 52:03 — Future of Work and AI Agents See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The Nobel Prize in physiology or medicine was awarded to three scientists for their work in immunology.  Daniel Griffin, MD, PhD, Chief of Infectious Disease for Island Infectious Diseases, the largest physician-owned Infectious Disease Specialist Group on Long Island, an infectious disease specialist and clinical instructor of medicine at Columbia University and president of Parasites Without Borders and co-host of the podcast "This Week in Virology", explains their breakthrough and what it means for future treatments for autoimmune diseases, cancer, and more. 

Elizabeth Marnik, also known as Science Whiz Liz, grew up unvaccinated, yet she is now an immunologist, science communicator, and advocate for vaccines–this is her story.    Host: Cindy Leifer Guest: Elizabeth Marnick Subscribe (free): Apple Podcasts, RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server More about Liz on her webpage ScienceWhizLiz on Instagram From the Science Classroom with Science Whiz Liz on Substack Time stamps by Jolene Ramsey. Thanks! Music by Tatami. Logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv Information on this podcast should not be construed as medical advice.

mRNA vaccines are not supposed to contain DNA. But Dr. Jessica Rose says a new study tested “32 vials of Pfizer and Moderna COVID products that included 16 unique lots… We did not only find DNA, we found it in ALL lots tested and most importantly, the DNA levels were all above pre-designated EMA thresholds of 10 ng/dose.” “We measured the amount of DNA in the vials using 2 methods… (qPCR and fluorometry),” she continues. “It was submitted as evidence on the congressional record by the honorable Senator Ron Johnson.” JP Sears is a comedian, author, and YouTuber known for his satirical take on politics, fitness, and faith. He hosts Awaken with JP on Rumble and YouTube. Follow at https://x.com/AwakenWithJP Dr. Jessica Rose is a Canadian researcher with a Bachelor's in Applied Mathematics and a Master's in Immunology from Memorial University of Newfoundland. She holds a PhD in Computational Biology from Bar Ilan University and completed postdoctoral research in Molecular Biology and Biochemistry. Find her at https://jessicasuniverse.com and follow at https://x.com/JesslovesMJK 「 SUPPORT OUR SPONSORS 」 Find out more about the brands that make this show possible and get special discounts on Dr. Drew's favorite products at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/sponsors⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠• FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/fatty15⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/paleovalley⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • VSHREDMD – Formulated by Dr. Drew: The Science of Cellular Health + World-Class Training Programs, Premium Content, and 1-1 Training with Certified V Shred Coaches! More at https://drdrew.com/vshredmd • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twc.health/drew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 「 MEDICAL NOTE 」 Portions of this program may examine countervailing views on important medical issues. Always consult your physician before making any decisions about your health. 「 ABOUT THE SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠) and Susan Pinsky (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/firstladyoflov⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠e⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Learn more about your ad choices. Visit megaphone.fm/adchoices

How do you hold on to hope while still being realistic about the work that needs to be done? Immunology researcher David Fajgenbaum and public health expert Celina de Sola discuss how they scaled personal missions into organizations making long-term impact on communities near and far. They explore how to stay motivated, discover your leadership style and uncover overlooked solutions hiding in plain sight. (This conversation is part of "TED Intersections," a series featuring thought-provoking conversations between experts navigating the ideas shaping our world.)Interested in learning more about upcoming TED events? Follow these links:TEDNext: ted.com/futureyouTEDAI Vienna: ted.com/ai-viennaTEDAI San Francisco: ted.com/ai-sf Hosted on Acast. See acast.com/privacy for more information.